HLX01 vs PF-05280586
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
HLX01 · Hanlikang
Marketed by Shanghai Henlius Biotech
NCT03522415 · Phase 3 · completed
This randomised, quadruple-blind trial compared HLX01 plus methotrexate with placebo plus methotrexate in 275 patients with rheumatoid arthritis. At 24 weeks, 60.7% of patients on HLX01 reached an ACR20 response against 35.9% on placebo (P<0.001), a clear result on a validated measure of disease activity.
No aligned efficacy figure on record for this race.
PF-05280586
Marketed by Pfizer
NCT01526057 · Phase 2 · completed
The 220-participant trial was randomized, quadruple-blind, and actively controlled with European- and US-sourced rituximab. The primary pharmacokinetic comparisons met the prespecified equivalence range for both peak concentration and total drug exposure, but these were surrogate measures rather than hard clinical outcomes, supporting a moderate evidence grade.
Reported efficacy
Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion); AUC 0-inf of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Rituximab-Pfizer 453 micrograms per milliliter (Standard Deviation 153) | Rituximab-EU 422 micrograms per milliliter (Standard Deviation 111) | Rituximab-US 430 micrograms per milliliter (Standard Deviation 163) (met)
Result source: NCT01526057
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HLX01 | PF-05280586 |
|---|---|---|
| ACR20 | 60.7% vs 35.9%a+24.8 vs placeboNCT03522415 | 77.1% vs 90%vs Rituximab-EUNCT0164392818 other results
|
| ACR50 | —Not posted · NCT03522415 | 51.4% vs 30%vs Rituximab-EUNCT0164392818 other results
|
| ACR70 | —Not posted · NCT03522415 | 22.9% vs 10%vs Rituximab-EUNCT0164392818 other results
|
| DAS28-CRP remission | —Not posted · NCT03522415 | 45.7% vs 20%vs Rituximab-EUNCT0164392811 other results
|
| HAQ-DI, change | —Not posted · NCT03522415 | -0.4 vs -0.5vs RituximabNCT015260576 other results
|
| Modified Sharp score, change | —Not posted · NCT03522415 | —Not reported |
ACR20
- HLX01
- 60.7% vs 35.9%a+24.8 vs placeboNCT03522415
- PF-05280586
- 77.1% vs 90%vs Rituximab-EUNCT01643928
18 other results
- 81.8% vs 90% NCT01643928
- 73.7% vs 90% NCT01643928
- 69.6% vs 77.4% NCT01643928
- 84.8% vs 77.4% NCT01643928
- 82.8% vs 77.4% NCT01643928
- 66.7% vs 71% NCT01643928
- 84.8% vs 71% NCT01643928
- 76.7% vs 71% NCT01643928
- 50% vs 59.4% NCT01643928
- 63.6% vs 59.4% NCT01643928
- 60% vs 59.4% NCT01643928
- 50% vs 60.3% NCT01526057
- 54.2% vs 62.2% NCT01526057
- 54.8% vs 67.6% NCT01526057
- 50.7% vs 70.3% NCT01526057
- 49.3% vs 60.8% NCT01526057
- 54.8% vs 56.8% NCT01526057
- 34.2% vs 33.8% NCT01526057
ACR50
- HLX01
- —Not posted · NCT03522415
- PF-05280586
- 51.4% vs 30%vs Rituximab-EUNCT01643928
18 other results
- 63.6% vs 30% NCT01643928
- 36.8% vs 30% NCT01643928
- 37.5% vs 41.9% NCT01643928
- 66.7% vs 41.9% NCT01643928
- 58.6% vs 41.9% NCT01643928
- 33.3% vs 51.6% NCT01643928
- 51.5% vs 51.6% NCT01643928
- 53.3% vs 51.6% NCT01643928
- 17.2% vs 28.1% NCT01643928
- 48.5% vs 28.1% NCT01643928
- 30% vs 28.1% NCT01643928
- 21% vs 38.1% NCT01526057
- 27.8% vs 37.8% NCT01526057
- 24.7% vs 36.5% NCT01526057
- 35.6% vs 40.5% NCT01526057
- 21.9% vs 32.4% NCT01526057
- 19.2% vs 16.2% NCT01526057
- 8.2% vs 5.4% NCT01526057
ACR70
- HLX01
- —Not posted · NCT03522415
- PF-05280586
- 22.9% vs 10%vs Rituximab-EUNCT01643928
18 other results
- 36.4% vs 10% NCT01643928
- 15.8% vs 10% NCT01643928
- 23.2% vs 32.3% NCT01643928
- 36.4% vs 32.3% NCT01643928
- 34.5% vs 32.3% NCT01643928
- 21.1% vs 22.6% NCT01643928
- 33.3% vs 22.6% NCT01643928
- 30% vs 22.6% NCT01643928
- 5.2% vs 12.5% NCT01643928
- 21.2% vs 12.5% NCT01643928
- 10% vs 12.5% NCT01643928
- 16.1% vs 17.5% NCT01526057
- 13.9% vs 23% NCT01526057
- 15.1% vs 18.9% NCT01526057
- 19.2% vs 28.4% NCT01526057
- 12.3% vs 17.6% NCT01526057
- 6.8% vs 6.8% NCT01526057
- 2.7% vs 2.7% NCT01526057
DAS28-CRP remission
- HLX01
- —Not posted · NCT03522415
- PF-05280586
- 45.7% vs 20%vs Rituximab-EUNCT01643928
11 other results
- 27.3% vs 20% NCT01643928
- 21.1% vs 20% NCT01643928
- 33.9% vs 46.7% NCT01643928
- 45.5% vs 46.7% NCT01643928
- 37.9% vs 46.7% NCT01643928
- 32.1% vs 38.7% NCT01643928
- 34.4% vs 38.7% NCT01643928
- 32.1% vs 38.7% NCT01643928
- 3.9% vs 10.7% NCT01643928
- 19.4% vs 10.7% NCT01643928
- 7.1% vs 10.7% NCT01643928
HAQ-DI, change
- HLX01
- —Not posted · NCT03522415
- PF-05280586
- -0.4 vs -0.5vs RituximabNCT01526057
6 other results
- -0.4 vs -0.6 NCT01526057
- -0.3 vs -0.6 NCT01526057
- -0.4 vs -0.6 NCT01526057
- -0.4 vs -0.5 NCT01526057
- -0.3 vs -0.3 NCT01526057
- -0.2 vs -0.2 NCT01526057
Modified Sharp score, change
- HLX01
- —Not posted · NCT03522415
- PF-05280586
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HLX01: 0 of 4 rows · PF-05280586: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | HLX01 | PF-05280586 |
|---|---|---|
| Dropout rate | — | 12.3%a NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 12 more results—PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 17.2%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 9.1%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 6.7%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | — | 4.1%a NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 12 more results—PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 3.4%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 0%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 6.7%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence |
| Serious AEs | — | 6.8%a NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 12 more results6.1%PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 12.9%PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 13.3%PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 6.7%PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 3.4%PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 3.4%PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 6.9%PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence 11.1%PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence 8.3%PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | — | a upper respiratory tract infection 9.6% fatigue 6.8% hypertension 5.5% NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 9 more resultsrheumatoid arthritis 9.1% vomiting 6.1% back pain 3% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 9.7% back pain 6.5% sinusitis 6.5% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 10% urinary tract infection 10% arthralgia 6.7% NCT01643928 · Phase na · registry result, not featured evidence diarrhoea 6.7% oropharyngeal pain 6.7% gastroenteritis 3.3% NCT01643928 · Phase na · registry result, not featured evidence diarrhoea 6.9% nausea 6.9% oropharyngeal pain 6.9% NCT01643928 · Phase na · registry result, not featured evidence upper respiratory tract infection 10.3% alanine aminotransferase increased 6.9% aspartate aminotransferase increased 6.9% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 6.9% urinary tract infection 6.9% fatigue 5.2% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 9.3% urinary tract infection 9.3% bronchitis 7.4% NCT01643928 · Phase na · registry result, not featured evidence bronchitis 10.4% rheumatoid arthritis 10.4% urinary tract infection 10.4% NCT01643928 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
PF-05280586
show 18 more results
show 18 more results
show 6 more results
show 18 more results
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 102 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX01's landscape · PF-05280586's landscape